Filings & corporate actions
78 results filed
CSVNext results · Q2 FY27
Expected 1 Nov 2026 – 13 Nov 2026
Estimate: filed 32–44 days after quarter end, last 5 times
Dividend
₹4.00 per share · last 1 Aug 2022
2026
- 11 AugresultsResults · Q1 FY27 · consolidated and standalone+13.1%NSE
- 14 JulshareholdingShareholding · 30 Jun 2026-2.6%NSE
- 22 MayresultsResults · Q4 FY26 · consolidated and standalone-3.1%NSE
- 13 AprshareholdingShareholding · 31 Mar 2026+0.3%NSE
- 5 FebresultsResults · Q3 FY26 · consolidated and standalone-7.8%NSE
- 9 JanshareholdingShareholding · 31 Dec 2025-1.2%NSE
Reaction to results · all yearsrose on day 0 in 27 of 78 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 11 Aug 2026 | +13.1% | +4.4% | +9.6% | 26.8× |
| Q4 FY26 | 22 May 2026 | -3.1% | -1.6% | +17.6% | 3.4× |
| Q3 FY26 | 5 Feb 2026 | -7.8% | -12.6% | -27.7% | 3.2× |
| Q2 FY26 | 11 Nov 2025 | +4.3% | +3.2% | -4.0% | 24.2× |
| Q1 FY26 | 4 Aug 2025 | -7.4% | -18.7% | -17.5% | 5.0× |
| Q4 FY25 | 22 May 2025 | +2.6% | -4.4% | -6.3% | 3.9× |
| Q3 FY25 | 6 Feb 2025 | +1.4% | -4.1% | -5.2% | 16.9× |
| Q2 FY25 | 13 Nov 2024 | 0.0% | -2.2% | -11.1% | 2.6× |
| Q1 FY25 | 8 Aug 2024 | -3.3% | -3.8% | -2.0% | 2.0× |
| Q4 FY24 | 22 May 2024 | -3.1% | -4.4% | -5.8% | 1.2× |
| Q3 FY24 | 5 Feb 2024 | +20.0% | +7.8% | +12.1% | 27.8× |
| Q2 FY24 | 1 Nov 2023 | -4.2% | -7.4% | -3.4% | 1.5× |
| Q1 FY24 | 14 Jul 2023 | +1.5% | +0.4% | +7.4% | 6.2× |
| Q4 FY23 | 23 May 2023 | +0.2% | +0.3% | -0.8% | 1.0× |
| Q3 FY23 | 6 Feb 2023 | -1.2% | +0.6% | -3.8% | 0.6× |
| Q2 FY23 | 11 Nov 2022 | -2.3% | +8.6% | -22.4% | 0.6× |
| Q1 FY23 | 9 Aug 2022 | -9.2% | -2.4% | +22.6% | 4.7× |
| Q4 FY22 | 27 May 2022 | +13.7% | +3.9% | +0.6% | 21.7× |
| Q3 FY22 | 29 Jan 2022 | -4.4% | -11.7% | -9.2% | 0.9× |
| Q2 FY22 | 3 Nov 2021 | -2.1% | -6.8% | +12.0% | 1.6× |
| Q1 FY22 | 31 Jul 2021 | -5.8% | -12.9% | -12.4% | 3.1× |
| Q4 FY21 | 29 May 2021 | -6.5% | -8.8% | -11.0% | 1.8× |
| Q3 FY21 | 30 Jan 2021 | +1.3% | +14.0% | +12.2% | 0.7× |
| Q2 FY21 | 1 Nov 2020 | -1.7% | -7.1% | +0.8% | 3.5× |
| Q1 FY21 | 4 Aug 2020 | -2.0% | -9.7% | -8.1% | 1.9× |
| Q4 FY20 | 20 Jun 2020 | -1.6% | +10.5% | +29.1% | 0.8× |
| Q3 FY20 | 3 Feb 2020 | -3.5% | -5.9% | -16.2% | 1.1× |
| Q2 FY20 | 2 Nov 2019 | -4.7% | -14.2% | -12.5% | 1.4× |
| Q1 FY20 | 27 Jul 2019 | -3.1% | -0.7% | -1.4% | 2.4× |
| Q4 FY19 | 24 May 2019 | -3.4% | -3.5% | -13.4% | 1.8× |
| Q3 FY19 | 6 Feb 2019 | +1.4% | -3.9% | -0.9% | 3.4× |
| Q2 FY19 | 9 Nov 2018 | -1.8% | -3.0% | -13.5% | 1.1× |
| Q1 FY19 | 7 Aug 2018 | -2.5% | -6.1% | +2.2% | 0.5× |
| Q4 FY18 | 27 Jun 2018 | -0.6% | +1.1% | -3.0% | 0.4× |
| Q3 FY18 | 9 Jan 2018 | 0.0% | +0.7% | +3.6% | 0.6× |
| Q2 FY18 | 6 Nov 2017 | -4.5% | -6.7% | -4.2% | 1.2× |
| Q1 FY18 | 18 Aug 2017 | -1.6% | -2.8% | +0.6% | 0.2× |
| Q4 FY17 | 19 Jun 2017 | -1.0% | -1.4% | +3.6% | 0.5× |
| Q3 FY17 | 23 Jan 2017 | +0.1% | -1.7% | -7.1% | 1.5× |
| Q2 FY17 | 24 Oct 2016 | +0.5% | +1.6% | -10.5% | 0.4× |
| Q1 FY17 | 1 Oct 2016 | +5.8% | +8.8% | +5.4% | 5.8× |
| Q4 FY16 | 23 May 2016 | -0.5% | -2.6% | -3.6% | 1.1× |
| Q3 FY16 | 27 Jan 2016 | -2.1% | -7.6% | -17.0% | 1.5× |
| Q2 FY16 | 19 Oct 2015 | -4.0% | -7.4% | -7.2% | 0.7× |
| Q1 FY16 | 13 Jul 2015 | +2.8% | +13.8% | +8.4% | 2.0× |
| Q4 FY15 | 11 May 2015 | -0.8% | -0.5% | -11.4% | 0.8× |
| Q3 FY15 | 19 Jan 2015 | -3.4% | -3.3% | -6.7% | 4.2× |
| Q2 FY15 | 21 Oct 2014 | -0.9% | -2.0% | +16.7% | 0.8× |
| Q1 FY15 | 14 Jul 2014 | -3.8% | +1.8% | +11.2% | 1.2× |
| Q4 FY14 | 12 May 2014 | +1.3% | -6.5% | -2.8% | 1.9× |
| Q3 FY14 | 20 Jan 2014 | -0.5% | -5.8% | -5.2% | 1.2× |
| Q2 FY14 | 21 Oct 2013 | -0.4% | +2.7% | +13.9% | 1.9× |
| Q1 FY14 | 23 Jul 2013 | +0.6% | +1.7% | -7.7% | 0.6× |
| Q4 FY13 | 21 May 2013 | -1.1% | -7.9% | -8.9% | 0.2× |
| Q3 FY13 | 18 Jan 2013 | -5.9% | -6.9% | -13.0% | 1.6× |
| Q2 FY13 | 22 Oct 2012 | +4.7% | -0.7% | -8.7% | 4.1× |
| Q1 FY13 | 24 Aug 2012 | -0.4% | -0.7% | +16.9% | 0.4× |
| Q4 FY12 | 14 May 2012 | +0.9% | +1.1% | -1.2% | 0.7× |
| Q3 FY12 | 23 Jan 2012 | -4.2% | -4.7% | -8.0% | 0.3× |
| Q2 FY12 | 22 Oct 2011 | -2.5% | -4.4% | -20.9% | 0.7× |
| Q1 FY12 | 28 Jul 2011 | -3.1% | -1.3% | -4.1% | 1.4× |
| Q4 FY11 | 14 May 2011 | -3.0% | -7.8% | -12.9% | 1.2× |
| Q3 FY11 | 17 Jan 2011 | -3.4% | -3.0% | -3.4% | 1.1× |
| Q2 FY11 | 18 Oct 2010 | -5.1% | +0.6% | +11.8% | 1.6× |
| Q1 FY11 | 22 Jul 2010 | -3.0% | -6.1% | -10.4% | 5.1× |
| Q4 FY10 | 10 May 2010 | +1.2% | +0.8% | +9.6% | 1.2× |
| Q3 FY10 | 19 Jan 2010 | +3.6% | +1.1% | -0.3% | 1.5× |
| Q2 FY10 | 22 Oct 2009 | -1.2% | -3.8% | -4.4% | 3.2× |
| Q1 FY10 | 22 Jul 2009 | +1.4% | +3.8% | +0.6% | 1.3× |
| Q4 FY09 | 21 May 2009 | +0.4% | +18.6% | +6.1% | 2.2× |
| Q3 FY09 | 22 Jan 2009 | +3.8% | -2.5% | -6.9% | 10.0× |
| Q2 FY09 | 23 Oct 2008 | +0.9% | -1.1% | -2.7% | 1.3× |
| Q1 FY09 | 17 Jul 2008 | +14.1% | +8.0% | +26.0% | 16.5× |
| Q4 FY08 | 12 May 2008 | -1.5% | +8.4% | +1.6% | 2.0× |
| Q3 FY08 | 31 Jan 2008 | -1.1% | -4.0% | -10.2% | 0.2× |
| Q2 FY08 | 18 Oct 2007 | -3.8% | -5.3% | -9.7% | 0.2× |
| Q1 FY08 | 19 Jul 2007 | +0.7% | -1.9% | -11.3% | 6.8× |
| Q4 FY07 | 17 May 2007 | +0.6% | -0.1% | -0.1% | 3.8× |
| Average | -0.6% | -1.8% | -2.2% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+20.1%
Profit YoY—
Interest cost YoY—
Revenue QoQ+10.0%
Profit QoQ+280.1%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Profit | — | — | — | — | — | — |
Key data
CSVOpen531.25
Day range531.25 – 556.20
52-week range278.20 – 687.20
From 52w high-20.2%
RSI (14)51.6
ATR (14)31.41
Volume60.2K
Avg volume (20D)3.14L
Rel volume0.19×
Volatility (1Y)49.4%
Turnover₹3.3Cr
SMA 50 / 200535.99 / 434.48
Delivery percentage
Latest · 6 Oct 202641.0%
20-day avg35.1%
1-year avg48.2%
Percentile (own history)24th
Range4.5–97.2%
Sessions1,731
Over the last 20 sessions UNICHEMLAB settled 35.1% of its traded quantity, which is ordinary for an NSE equity. Its one-year average is 48.2%, so recent sessions are running 13.1 points lower than usual. The latest session ranks higher than 24% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +3.13% | +2.18% | +0.03% | +14.85% | +83.74% | +14.45% |
Valuation
CSVMarket cap₹3,859 Cr
P/E (TTM)12.7
EPS (TTM)43.29
Shares outstanding7.04Cr
Listed7 Feb 2001
Ownership
CSVPromoter—
Promoter Δ QoQ—
Public—
FII—
DII—
Pledged—
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 579.0 | 521.2 | 575.1 | 632.6 |
| YoY chg | — | — | -2.1% | +20.1% |
| Net profit (₹ Cr) | (11.9) | 264.3 | 10.9 | 41.5 |
| YoY chg | — | — | -79.4% | — |
| Net margin | -2.1% | 50.7% | 1.9% | 6.6% |
| EPS | -1.69 | 37.47 | 1.55 | 6.61 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 70.22% · public 29.78%2021-092026-06
- Promoter
- Public and others
- Promoter
- 70.22%
- Public
- 29.78%
- Promoter change
- 0.00 pp
- Filed
- 14 Jul 2026
- FII
- 0.90%
- DII
- 10.46%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 415.6 | 434.4 | 431.7 | 446.4 | 462.2 | 533.1 | 587.2 | 526.6 | 579.0 | 521.2 | 575.1 | 632.6 | |
| Other income | 5.5 | 11.3 | 6.2 | 3.9 | 8.8 | 13.6 | 9.3 | 6.8 | 21.0 | 11.8 | 23.5 | 15.6 | |
| Total income | 421.2 | 445.7 | 437.9 | 450.3 | 471.0 | 546.7 | 596.4 | 533.4 | 599.9 | 533.0 | 598.6 | 648.2 | |
| Total expenses | 443.0 | 429.7 | 438.1 | 435.3 | 438.0 | 484.9 | 538.6 | 542.4 | 552.5 | 515.1 | 567.4 | 599.2 | |
| └ Finance costs | 6.7 | 5.6 | 4.6 | 4.0 | 4.8 | 6.8 | 5.5 | 6.5 | 8.2 | 7.4 | 9.4 | 6.6 | |
| └ Depreciation | 29.5 | 27.9 | 27.2 | 28.3 | 28.5 | 30.5 | 29.7 | 31.8 | 31.5 | 31.3 | 30.6 | 29.9 | |
| Profit before tax | (21.9) | 84.0 | (125.9) | 15.0 | 33.0 | 61.9 | 57.8 | (9.0) | (10.8) | 293.4 | 18.8 | 49.0 | |
| Tax expense | 2.6 | (0.0) | 3.4 | 5.7 | 2.5 | 4.0 | 4.8 | 1.5 | 1.1 | 29.1 | 7.9 | 7.5 | |
| Net profit | (24.5) | 84.0 | (129.3) | 9.3 | 30.5 | 57.9 | 53.0 | (10.5) | (11.9) | 264.3 | 10.9 | 41.5 | |
| EPS | -3.48 | 11.93 | -18.37 | 1.31 | 4.34 | 8.22 | 7.52 | -1.49 | -1.69 | 37.54 | 1.55 | 6.61 | |
| Net margin | -5.89% | 19.34% | -29.95% | 2.07% | 6.60% | 10.85% | 9.02% | -1.99% | -2.05% | 50.71% | 1.90% | 6.56% | |
| PBT margin | -5.26% | 19.33% | -29.16% | 3.36% | 7.14% | 11.60% | 9.84% | -1.71% | -1.87% | 56.30% | 3.27% | 7.74% | |
| Tax rate | — | -0.03% | — | 38.29% | 7.58% | 6.47% | 8.36% | — | — | 9.93% | 41.94% | 15.35% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 11 Aug 2026.
UNICHEMLAB at a glance
- UNICHEMLAB closed at ₹548.1 on 6 Oct 2026, +3.13% on the day, +14.4% over one year, 20.2% below its 52-week high of ₹687.2.
- Delivery was 41.0% of traded quantity on 6 Oct 2026, the 24th percentile of its own 1,731 sessions with a reading (20-session average 35.1%, 1-year average 48.2%).
- Market capitalisation is ₹3,859 crore at a trailing P/E of 12.7 (trailing EPS ₹43.29).
- Q1 FY27 results (consolidated, filed 11 Aug 2026): revenue ₹633 crore (+20.1% year on year), net profit ₹41 crore; the price moved +13.1% on the first session after.
- Promoters held 70.22% at 30 Jun 2026, unchanged on the previous filing.
- Q2 FY27 results are expected between 1 Nov 2026 and 13 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE351A01035
SeriesEQ
Listed7 Feb 2001
History from10 Jan 1995
Sessions7,546
Turnover rank#833
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE